118 related articles for article (PubMed ID: 24435839)
21. The Ras antagonist S-farnesylthiosalicylic acid induces inhibition of MAPK activation.
Gana-Weisz M; Haklai R; Marciano D; Egozi Y; Ben-Baruch G; Kloog Y
Biochem Biophys Res Commun; 1997 Oct; 239(3):900-4. PubMed ID: 9367867
[TBL] [Abstract][Full Text] [Related]
22. Novel Ras antagonist blocks human melanoma growth.
Jansen B; Schlagbauer-Wadl H; Kahr H; Heere-Ress E; Mayer BX; Eichler H; Pehamberger H; Gana-Weisz M; Ben-David E; Kloog Y; Wolff K
Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14019-24. PubMed ID: 10570191
[TBL] [Abstract][Full Text] [Related]
23. Stringent structural requirements for anti-Ras activity of S-prenyl analogues.
Aharonson Z; Gana-Weisz M; Varsano T; Haklai R; Marciano D; Kloog Y
Biochim Biophys Acta; 1998 Feb; 1406(1):40-50. PubMed ID: 9545527
[TBL] [Abstract][Full Text] [Related]
24. Ras inhibition enhances autophagy, which partially protects cells from death.
Schmukler E; Grinboim E; Schokoroy S; Amir A; Wolfson E; Kloog Y; Pinkas-Kramarski R
Oncotarget; 2013 Jan; 4(1):145-55. PubMed ID: 23370967
[TBL] [Abstract][Full Text] [Related]
25. Phenotypic reversion of invasive neurofibromin-deficient schwannoma by FTS: Ras inhibition reduces BMP4/Erk/Smad signaling.
Barkan B; Kloog Y; Ehrlich M
Mol Cancer Ther; 2011 Aug; 10(8):1317-26. PubMed ID: 21632464
[TBL] [Abstract][Full Text] [Related]
26. Farnesylthiosalicylic acid sensitizes hepatocarcinoma cells to artemisinin derivatives.
Wu L; Pang Y; Qin G; Xi G; Wu S; Wang X; Chen T
PLoS One; 2017; 12(2):e0171840. PubMed ID: 28182780
[TBL] [Abstract][Full Text] [Related]
27. Ras inhibitor farnesylthiosalicylic acid conjugated with IR783 dye exhibits improved tumor-targeting and altered anti-breast cancer mechanisms in mice.
Huang QJ; Liao GC; Zhuang XR; Yang ML; Yao JJ; Deng JH; Zhang YM; Wang Y; Qi XX; Pan DF; Guan Y; Huang ZY; Zhang FX; Liu ZQ; Lu LL
Acta Pharmacol Sin; 2022 Jul; 43(7):1843-1856. PubMed ID: 34845369
[TBL] [Abstract][Full Text] [Related]
28. Composite fiber structures with antiproliferative agents exhibit advantageous drug delivery and cell growth inhibition in vitro.
Kraitzer A; Kloog Y; Haklai R; Zilberman M
J Pharm Sci; 2011 Jan; 100(1):133-49. PubMed ID: 20623695
[TBL] [Abstract][Full Text] [Related]
29. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.
Rotblat B; Ehrlich M; Haklai R; Kloog Y
Methods Enzymol; 2008; 439():467-89. PubMed ID: 18374183
[TBL] [Abstract][Full Text] [Related]
30. Vitamin D and S-farnesylthiosalicylic acid have a synergistic effect on hepatic stellate cells proliferation.
Neeman R; Abramovitch S; Sharvit E; Elad-Sfadia G; Haklai R; Kloog Y; Reif S
Dig Dis Sci; 2014 Oct; 59(10):2462-9. PubMed ID: 24942325
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological evaluation of betulonic acid derivatives as antitumor agents.
Yang SJ; Liu MC; Zhao Q; Hu DY; Xue W; Yang S
Eur J Med Chem; 2015; 96():58-65. PubMed ID: 25874331
[TBL] [Abstract][Full Text] [Related]
32. RAS Promotes Proliferation and Resistances to Apoptosis in Meningioma.
Jiang C; Song T; Li J; Ao F; Gong X; Lu Y; Zhang C; Chen L; Liu Y; He H; Huang O
Mol Neurobiol; 2017 Jan; 54(1):779-787. PubMed ID: 27021020
[TBL] [Abstract][Full Text] [Related]
33. Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis.
Blum R; Jacob-Hirsch J; Rechavi G; Kloog Y
Mol Cancer Ther; 2006 Sep; 5(9):2337-47. PubMed ID: 16985068
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of novel 2'-hydroxy group substituted 2-pyridone derivatives as anticancer agents.
Lv Z; Zhang Y; Zhang M; Chen H; Sun Z; Geng D; Niu C; Li K
Eur J Med Chem; 2013 Sep; 67():447-53. PubMed ID: 23920246
[TBL] [Abstract][Full Text] [Related]
35. Farnesylthiosalicylic acid inhibits the growth of human Merkel cell carcinoma in SCID mice.
Jansen B; Heere-Ress E; Schlagbauer-Wadl H; Halaschek-Wiener J; Waltering S; Moll I; Pehamberger H; Marciano D; Kloog Y; Wolff K
J Mol Med (Berl); 1999 Nov; 77(11):792-7. PubMed ID: 10619439
[TBL] [Abstract][Full Text] [Related]
36. RAS inhibitors: potential for cancer therapeutics.
Kloog Y; Cox AD
Mol Med Today; 2000 Oct; 6(10):398-402. PubMed ID: 11006529
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis and biological activities of sorafenib derivatives as antitumor agents.
Yao J; He Z; Chen J; Sun W; Fang H; Xu W
Bioorg Med Chem Lett; 2012 Nov; 22(21):6549-53. PubMed ID: 23021967
[TBL] [Abstract][Full Text] [Related]
38. Ras inhibition in hepatocarcinoma by S-trans-trans-farnesylthiosalicyclic acid: association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis.
Stärkel P; Charette N; Borbath I; Schneider-Merck T; De Saeger C; Abarca J; Leclercq I; Horsmans Y
Mol Carcinog; 2012 Oct; 51(10):816-25. PubMed ID: 21882255
[TBL] [Abstract][Full Text] [Related]
39. Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes.
Aizman E; Mor A; Levy A; George J; Kloog Y
Oncotarget; 2012 Feb; 3(2):144-57. PubMed ID: 22323550
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of the Ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats.
da Silva Morais A; Saliez A; Leclercq I; Horsmans Y; Stärkel P
Clin Sci (Lond); 2008 Jan; 114(1):73-83. PubMed ID: 17678500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
